share_log

Stephens & Co. Maintains Overweight on Akoya Biosciences, Lowers Price Target to $9

Benzinga ·  Nov 13, 2023 09:13

Stephens & Co. analyst Mason Carrico maintains Akoya Biosciences (NASDAQ:AKYA) with a Overweight and lowers the price target from $14 to $9.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment